Annovis Bio, Inc. (ANVS) stock
ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.74−0.01 (-0.91%)
Close on Nov 17, 2026Market cap $31.66MP/E –Yield –
Annovis Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Annovis Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$43.34M. For fiscal 2025 it was -$25.62M. The highest annual figure on record is -$476.54K in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$25.62M | – |
| FY2024 | Dec 31, 2024 | -$21.89M | – |
| FY2023 | Dec 31, 2023 | -$39.97M | – |
| FY2022 | Dec 31, 2022 | -$17.31M | – |
| FY2021 | Dec 31, 2021 | -$9.13M | – |
| FY2020 | Dec 31, 2020 | -$3.97M | – |
| FY2019 | Dec 31, 2019 | -$476.54K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.91M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.03M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.77M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -$765.95K | – |
| Q3 FY2020 | Sep 30, 2020 | -$922.66K | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$970.41K | – |
| Q4 FY2019 | Dec 31, 2019 | -$52.53K | – |
| Q3 FY2019 | Sep 30, 2019 | -$44.68K | – |
| Q2 FY2019 | Jun 30, 2019 | -$150.59K | – |
| Q1 FY2019 | Mar 31, 2019 | -$228.74K | – |
See a number that looks wrong?